Want to see RNAC full AI Analyst Report?
RNAC Stock Chart & Stats
$7.04
-$0.34(-1.95%)
At close: 4:00 PM EST
$7.04
-$0.34(-1.95%)
Day’s Range― - ―
52-Week Range$5.60 - $15.57
Previous CloseN/A
Volume45.37K
Average Volume (3M)358.02K
Market Cap
$311.15M
Enterprise Value$183.50M
Total Cash (Recent Filing)$118.64M
Total Debt (Recent Filing)$11.86M
Price to Earnings (P/E)―
Beta2.72
Next Earnings
Aug 06, 2026EPS Estimate
-0.88Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.79
Shares Outstanding29,381,514
10 Day Avg. Volume743,292
30 Day Avg. Volume358,025
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)-1.48
Price to Sales (P/S)66.95
P/FCF Ratio-2.36
Enterprise Value/Market Cap0.59
Enterprise Value/Revenue103.38
Enterprise Value/Gross Profit-16.65
Enterprise Value/Ebitda-1.16
Forecast
1Y Price Target
$33.83Price Target Upside380.59% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-4.15
Revenue Forecast (FY)$549.50K
Bulls Say, Bears Say
Bulls Say
In‑vivo CAR‑T Licensing AllianceThe WestGene licensing alliance creates a structural pathway to generate CAR‑T in vivo using Cartesian’s mRNA payloads and WestGene’s LNP delivery. Eliminating ex‑vivo manufacturing can materially lower complexity and cost, accelerate timelines across programs, and expand the company’s addressable autoimmune indications over multiple years.
Material Non‑dilutive Credit FacilityThe up to $150M senior secured facility, with $50M initial funding, materially extends operational runway into 2028. This non‑dilutive capital (limited conversion rights) supports completion of late‑stage trials and precommercial activities, reducing immediate financing pressure and enabling focus on clinical milestones that determine long‑term viability.
Board And Governance ContinuityHigh shareholder turnout and re‑election of directors, plus ratification of Ernst & Young, signal governance stability and investor backing. Strong governance continuity is important for development‑stage biotech to maintain regulatory discipline, consistent clinical strategy execution, and reliable financial reporting through upcoming pivotal catalysts.
Bears Say
Persistent Heavy Cash BurnSustained negative operating and free cash flow at scale indicates the company cannot self‑fund development and will repeatedly rely on external financing. Over a multi‑quarter horizon, this creates recurring dilution or leverage risk, constrains strategic optionality, and forces prioritization of programs based on near‑term funding rather than long‑term potential.
Negative Equity And Strained Balance SheetMaterial negative equity reflects accumulated losses and raises recapitalization risk. Even with modest nominal debt, negative equity undermines financial flexibility, limits borrowing capacity without costly covenants or dilution, and increases the probability that the company must pursue equity issuance or onerous financing terms ahead of key trial readouts.
Deteriorating Revenue And Deep LossesDeclining revenue and a shift to deeply negative margins show weakening earnings quality. For a biotech reliant on R&D and external funding, falling top‑line and persistent losses reduce internal runway, make it harder to justify premium financing, and increase execution risk if clinical results or partnerships do not rapidly validate the strategy.
Cartesian Therapeutics News
RNAC FAQ
What was Cartesian Therapeutics, Inc.’s price range in the past 12 months?
Cartesian Therapeutics, Inc. lowest stock price was $5.60 and its highest was $15.57 in the past 12 months.
What is Cartesian Therapeutics, Inc.’s market cap?
Cartesian Therapeutics, Inc.’s market cap is $311.15M.
When is Cartesian Therapeutics, Inc.’s upcoming earnings report date?
Cartesian Therapeutics, Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 30 days.
How were Cartesian Therapeutics, Inc.’s earnings last quarter?
Cartesian Therapeutics, Inc. released its earnings results on May 07, 2026. The company reported -$1.46 earnings per share for the quarter, missing the consensus estimate of -$0.87 by -$0.59.
Is Cartesian Therapeutics, Inc. overvalued?
According to Wall Street analysts Cartesian Therapeutics, Inc.’s price is currently Undervalued.
Does Cartesian Therapeutics, Inc. pay dividends?
Cartesian Therapeutics, Inc. does not currently pay dividends.
What is Cartesian Therapeutics, Inc.’s EPS estimate?
Cartesian Therapeutics, Inc.’s EPS estimate is -0.88.
How many shares outstanding does Cartesian Therapeutics, Inc. have?
Cartesian Therapeutics, Inc. has 29,381,514 shares outstanding.
What happened to Cartesian Therapeutics, Inc.’s price movement after its last earnings report?
Cartesian Therapeutics, Inc. reported an EPS of -$1.46 in its last earnings report, missing expectations of -$0.87. Following the earnings report the stock price went down -2.158%.
Which hedge fund is a major shareholder of Cartesian Therapeutics, Inc.?
Currently, no hedge funds are holding shares in RNAC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cartesian Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$33.83 (380.59% Upside)
$33.83 (380.59% Upside)
Blogger Sentiment
Bullish
RNAC Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 22.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 5.5%
Last 30 Days ▲ 21.7%
Last 30 Days ▲ 21.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-6.86%
12-Months-Change
Fundamentals
Return on Equity
194.13%
Trailing 12-Months
Asset Growth
-29.51%
Trailing 12-Months
Company Description
Cartesian Therapeutics, Inc.
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company’s lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, which is in phase 1 trials, an autologous autologous B cell maturation antigen (BCMA) directed mRNA CAR-T to treat patients with multiple myeloma. The company is headquartered in Frederick, Maryland.
RNAC Stock 12 Month Forecast
Average Price Target
$33.83
▲(380.59% Upside)
Technical Analysis
Puma Biotechnology
―
DBV Technologies SA - American
―
Voyager Therapeutics
―
Atea Pharmaceuticals
―
Vor Biopharma
―
Ownership Overview
44.17% Insiders
7.32% Mutual Funds
3.32% Other Institutional Investors
40.89% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---